CB2 pointed out that its clinical services remain open to servicing patients in each operating State, currently via telehealth and telemedicine
() (OTCQB:CBIIF) has said that, due to circumstances created by the coronavirus (COVID-19) pandemic it will not be filing its financial statements for the fiscal year ended December 31, 2020 by the scheduled due date of April 30, 2020.
The company said it expects to file the financial reports on or about June 12, 2020, and until then, as required, its management and other insiders will be subject to a trading black-out.
READ: CB2 Insights launches medical cannabis industry’s first interactive dashboard to offer patient insights
Other than as previously disclosed, the company added, there have been no material business developments since the date of its most recent filing of its interim financial statements.
CB2 pointed out that its clinical services remain open to servicing patients in each operating State, currently via telehealth and telemedicine due to State requirements for respecting social distancing.
The company said it continues to be focused on execution with a current focus on cash management for operations and staff.
It concluded: "With the uncertainty of COVID-19 and its impact both in the short and long-term to all businesses, the Company wants to certainly provide confidence to our investment community to continue to execute in the best way possible, and deal with the intermittent challenges in order to ensure CB2 Insights achieves its long-term objectives."
